| Name | Market Cap | Current Price | P/E Ratio | Revenue Growth 1Y | Net Margin | ROE | FCF Yield | Debt/Equity |
|---|---|---|---|---|---|---|---|---|
| OSCROscar Health, Inc. | 4.39B | 17.42 | 182.03 | 56.54% | -2.16% | -23.77% | 21.62% | 0.29 |
| CLOVClover Health Investments, Corp. | 1.11B | 2.62 | -29.84 | 8.77% | -3.29% | -17.11% | 2.99% | |
| ALHCAlignment Healthcare, Inc. | 4.5B | 22.50 | -33.58 | 48.25% | -0.57% | -12.86% | 3.26 |
| Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | |
|---|---|---|---|---|---|---|
| Revenue | 553.78M | 589.64M | 1.92B | 4.13B | 5.86B | 9.18B |
| Revenue Growth % | - | 0.06% | 2.26% | 1.15% | 0.42% | 0.57% |
| Medical Costs & Claims | 0 | 0 | 0 | 0 | 0 | 0 |
| Medical Cost Ratio % | - | - | - | - | - | - |
| Gross Profit | 553.78M | 589.64M | 1.92B | 4.13B | 5.86B | 9.18B |
| Gross Margin % | - | - | - | - | - | - |
| Gross Profit Growth % | - | 0.06% | 2.26% | 1.15% | 0.42% | 0.57% |
| Operating Expenses | 813.17M | 995.42M | 2.49B | 4.74B | 6.13B | 9.14B |
| OpEx / Revenue % | - | - | - | - | - | - |
| Depreciation & Amortization | 6.9M | 11.29M | 14.61M | 15.28M | 30.69M | 32.15M |
| Combined Ratio % | - | - | - | - | - | - |
| Operating Income | -259.39M | -405.78M | -570.58M | -610.08M | -267.3M | 33.43M |
| Operating Margin % | - | - | - | - | - | - |
| Operating Income Growth % | - | -0.56% | -0.41% | -0.07% | 0.56% | 1.13% |
| EBITDA | -252.49M | -394.5M | -555.98M | -594.79M | -236.61M | 65.57M |
| EBITDA Margin % | - | - | - | - | - | - |
| Interest Expense | 0 | 3.51M | 4.72M | 22.62M | 24.6M | 23.73M |
| Non-Operating Income | 0 | -3.51M | -4.72M | -22.62M | -24.6M | -23.73M |
| Pretax Income | -259.39M | -405.78M | -570.58M | -610.08M | -267.3M | 33.43M |
| Pretax Margin % | - | - | - | - | - | - |
| Income Tax | 1.79M | 1.04M | 846K | -523K | 3.29M | 7.3M |
| Effective Tax Rate % | - | - | - | - | - | - |
| Net Income | -261.18M | -406.82M | -572.61M | -606.27M | -270.73M | 25.43M |
| Net Margin % | - | - | - | - | - | - |
| Net Income Growth % | - | -0.56% | -0.41% | -0.06% | 0.55% | 1.09% |
| EPS (Diluted) | -1.09 | -1.70 | -3.19 | -2.87 | -1.22 | 0.10 |
| EPS Growth % | - | -0.56% | -0.88% | 0.1% | 0.57% | 1.08% |
| EPS (Basic) | -8.93 | -1.70 | -3.19 | -2.87 | -1.22 | 0.11 |
| Diluted Shares Outstanding | 239.31M | 239.31M | 178.97M | 212.47M | 221.66M | 265.85M |
| Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | |
|---|---|---|---|---|---|---|
| Total Assets | 1.35B | 2.27B | 3.32B | 4.53B | 3.6B | 4.84B |
| Asset Growth % | - | 0.69% | 0.46% | 0.36% | -0.2% | 0.34% |
| Total Investment Assets | 363.23M | 692.13M | 1.43B | 2.79B | 1.06B | 2.44B |
| Long-Term Investments | 333.75M | 366.39M | 587.09M | 1.4B | 689.83M | 1.82B |
| Short-Term Investments | 333.75M | 366.39M | 587.09M | 1.4B | 689.83M | 624.46M |
| Total Current Assets | 0 | 0 | 0 | 4.12B | 0 | 2.85B |
| Cash & Equivalents | 336.64M | 826.33M | 1.1B | 1.56B | 1.87B | 1.53B |
| Receivables | 1000K | 1000K | 1000K | 1000K | 1000K | 1000K |
| Other Current Assets | -725.59M | -1.29B | -2.3B | 1.12B | -3.05B | 377.64M |
| Goodwill & Intangibles | 0 | 0 | 0 | 0 | 0 | 0 |
| Goodwill | 0 | 0 | 0 | 0 | 0 | 0 |
| Intangible Assets | 0 | 0 | 0 | 0 | 0 | 0 |
| PP&E (Net) | 33.08M | 35.81M | 46.61M | 59.89M | 61.93M | 66.79M |
| Other Assets | -366.83M | -402.2M | -633.7M | -1.05B | -751.76M | 113.28M |
| Total Liabilities | 2.29B | 3.57B | 1.93B | 3.63B | 2.8B | 3.82B |
| Total Debt | 0 | 142.49M | 0 | 298M | 298.78M | 299.56M |
| Net Debt | -336.64M | -683.84M | -1.1B | -1.26B | -1.57B | -1.23B |
| Long-Term Debt | 0 | 142.49M | 0 | 298M | 298.78M | 299.56M |
| Short-Term Debt | 0 | 0 | 0 | 0 | 0 | 0 |
| Total Current Liabilities | 0 | 0 | 0 | 3.26B | 0 | 3.17B |
| Accounts Payable | 589.07M | 655.23M | 718.81M | 1.37B | 1.03B | 1.4B |
| Deferred Revenue | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Current Liabilities | -887.7M | -1.37B | -1.51B | 381.05M | -2.08B | 215.28M |
| Deferred Taxes | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Liabilities | 0 | -142.49M | 0 | 72.28M | -298.78M | 61.28M |
| Total Equity | -945.14M | -1.3B | 1.39B | 892.4M | 806.12M | 1.02B |
| Equity Growth % | - | -0.37% | 2.07% | -0.36% | -0.1% | 0.26% |
| Shareholders Equity | -945.14M | -1.3B | 1.39B | 890.38M | 803.97M | 1.01B |
| Minority Interest | 0 | 0 | 5.29M | 2.02M | 2.15M | 2.84M |
| Retained Earnings | -1.01B | -1.43B | -2B | -2.61B | -2.88B | -2.85B |
| Common Stock | 2K | 2K | 2K | 2K | 2K | 2K |
| Accumulated OCI | -27K | 879K | -3.67M | -9.71M | 1.31M | -1.83M |
| Return on Equity (ROE) | - | - | -11.85% | -0.53% | -0.32% | 0.03% |
| Return on Assets (ROA) | -0.19% | -0.22% | -0.2% | -0.15% | -0.07% | 0.01% |
| Equity / Assets | - | - | - | - | - | - |
| Debt / Equity | - | - | - | 0.33x | 0.37x | 0.29x |
| Book Value per Share | -3.95 | -5.42 | 7.78 | 4.20 | 3.64 | 3.82 |
| Tangible BV per Share | - | - | - | - | - | - |
| Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | |
|---|---|---|---|---|---|---|
| Cash from Operations | -165.37M | 222.73M | -181.75M | 380.35M | -272.16M | 978.19M |
| Operating CF Growth % | - | 2.35% | -1.82% | 3.09% | -1.72% | 4.59% |
| Operating CF / Revenue % | - | - | - | - | - | - |
| Net Income | -261.18M | -406.82M | -571.43M | -609.55M | -270.59M | 26.12M |
| Depreciation & Amortization | 6.9M | 11.29M | 14.61M | 15.28M | 30.69M | 32.15M |
| Stock-Based Compensation | 33.56M | 35.87M | 86.3M | 112.33M | 159.68M | 109.82M |
| Deferred Taxes | -426K | -67K | -101K | -165K | 58K | -2.34M |
| Other Non-Cash Items | -6.43M | 6.77M | 41.19M | 7.46M | 86K | -26.42M |
| Working Capital Changes | 62.21M | 575.7M | 247.7M | 855M | -192.09M | 838.86M |
| Cash from Investing | 150.51M | -344.71M | -774.51M | -226.52M | 577.19M | -1.39B |
| Capital Expenditures | -26M | -14.02M | -25.89M | -29.01M | -25.58M | -27.9M |
| Acquisitions | 0 | 0 | 7.23M | 0 | 0 | 0 |
| Purchase of Investments | -877.67M | -1B | -1.81B | -1.19B | -836.98M | -2.13B |
| Sale/Maturity of Investments | 1000K | 1000K | 1000K | 1000K | 1000K | 1000K |
| Other Investing | -7.08M | -1.24M | -555K | 1.12M | -2.28M | 3.93M |
| Cash from Financing | -2.12M | 611.71M | 1.24B | 301.11M | 6.45M | 68.39M |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 | 0 |
| Share Repurchases | -2.99M | 0 | 0 | 0 | 0 | 0 |
| Stock Issued | 0 | 0 | 1.35B | 0 | 0 | 68.39M |
| Debt Issuance (Net) | 0 | 1000K | -1000K | 1000K | 0 | 0 |
| Other Financing | 873K | 89.04M | 43.56M | -3.89M | 6.45M | 0 |
| Net Change in Cash | -16.98M | 489.73M | 282.45M | 454.94M | 311.47M | -340.85M |
| Exchange Rate Effect | 0 | 0 | 0 | 0 | 0 | 0 |
| Cash at Beginning | 370.36M | 353.38M | 843.11M | 1.13B | 1.58B | 1.89B |
| Cash at End | 353.38M | 843.11M | 1.13B | 1.58B | 1.89B | 1.55B |
| Free Cash Flow | -191.37M | 208.71M | -207.63M | 351.34M | -297.74M | 950.3M |
| FCF Growth % | - | 2.09% | -1.99% | 2.69% | -1.85% | 4.19% |
| FCF Margin % | - | - | - | - | - | - |
| FCF per Share | -0.8 | 0.87 | -1.16 | 1.65 | -1.34 | 3.57 |
| Metric | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|---|
| Combined Ratio | 146.84% | 168.82% | 129.7% | 114.79% | 104.56% | 99.64% |
| Medical Cost Ratio | 0% | 0% | 0% | 0% | 0% | 0% |
| Return on Equity (ROE) | - | - | -1185.16% | -53.07% | -31.88% | 2.79% |
| Return on Assets (ROA) | -19.39% | -22.48% | -20.47% | -15.45% | -6.66% | 0.6% |
| Equity / Assets | -70.17% | -57.03% | 41.92% | 19.71% | 22.38% | 21% |
| Book Value / Share | -3.95 | -5.42 | 7.78 | 4.2 | 3.64 | 3.82 |
| Debt / Equity | - | - | - | 0.33x | 0.37x | 0.29x |
| Revenue Growth | - | 6.48% | 225.78% | 114.77% | 42.11% | 56.54% |
Oscar Health, Inc. (OSCR) has a price-to-earnings (P/E) ratio of 182.0x. This suggests investors expect higher future growth.
Oscar Health, Inc. (OSCR) grew revenue by 56.5% over the past year. This is strong growth.
Oscar Health, Inc. (OSCR) reported a net loss of $244.1M for fiscal year 2024.
Oscar Health, Inc. (OSCR) has a return on equity (ROE) of 2.8%. This is below average, suggesting room for improvement.
Oscar Health, Inc. (OSCR) has a combined ratio of 0.0%. A ratio below 100% indicates underwriting profitability.